Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price shot up 0.5% on Monday . The company traded as high as $87.00 and last traded at $86.22. 252,817 shares were traded during mid-day trading, an increase of 34% from the average session volume of 189,291 shares. The stock had previously closed at $85.75.
Gemini Therapeutics Stock Performance
The firm has a market capitalization of $3.74 billion, a PE ratio of -86.22 and a beta of -0.12. The business’s 50 day moving average is $69.07 and its two-hundred day moving average is $58.32.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- Stock Sentiment Analysis: How it Works
- Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate
- What is MarketRank™? How to Use it
- The Best Local Butchers for Thanksgiving [2025 Survey]
- Health Care Stocks Explained: Why You Might Want to Invest
- $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
